En 
繁
简
Drug discovery
Drug discovery

Drug discovery

Prof LI Min

Prof LI Min

Email: limin@hkbu.edu.hk

Website: https://scholars.hkbu.edu.hk/en/persons/LIMIN

Prof LI Min
Associate Dean (Teaching and Learning) of Chinese Medicine;
Professor, Teaching and Research Division;
Director, Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research;
Director, Bachelor of Chinese Medicine & Bachelor of Science (Hons) in Biomedical Science Programme;
Director, Master of Chinese Medicine Programme

Prof. Li Min obtained her Bachelor's degree from the Henan University of Traditional Chinese Medicine (TCM), China, in 1985, her Master's degree in Chinese Medicine at the Guangzhou University of Chinese Medicine, China, in 1988 and her PhD degree in Cardiology at the School of Medicine, Tokai University, Japan, in 2001. Then she joined the School of Chinese Medicine, Hong Kong Baptist University, where she is currently Associate Dean of School of Chinese Medicine, Programme Director of Bachelor of Chinese Medicine & Bachelor of Science (Hons) in Biomedical Science and Master of Chinese Medicine programmes, and Director of Mr. and Mrs. Ko Chi Ming Centre for Parkinson's Disease Research. Prof. Li received an Award of the Distinguished Female Chinese Medicine Practitioner by the China Association of Chinese medicine in 2007, School's Award for Outstanding Performance in Scholarly Work in 2012 and President's Award for Outstanding Performance in Teaching from Hong Kong Baptist University in 2013. Prof. Li's clinical specialty is in Chinese medicine treatment of neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD) and vascular dementia (VD), as well as on cardio-cerebrovascular diseases. For more information please refer to her lab: http://cpdr.hkbu.edu.hk

+ More Information
  • Neurodegenerative Diseases Including Parkinson's Disease (PD) and Alzheimer's Disease (AD).
  • Chinese Herbal Medicine for Prevention and Treatment of Neurodegenerative Diseases.
  • Development of Molecular Targets for Drug Discovery from TCM for Neurodegenerative Diseases.
  • Citations: 18,034
  • h-index: 44
  • i10-index: 127

Iyaswamy A, Krishnamoorthi SK, Zhang H, Sreenivasmurthy SG, Zhu Z, Liu J, Su CF, Wang ZY, Cheung KH, Song JX*, Durairajan SSK* & Li M* (2021) “ Qingyangshen mitigates Amyloid-β and Tau aggregate defects involving PPARα-TFEB activation in transgenic mice of Alzheimer's disease”. Phytomed. 3 July 2021.doi:10.1016/j.phymed.2021.153648

Tong BCK, Wu JX, Huang SY, Dong R, Malampati S, Iyaswamy A, Krishnamoorthi SK, Sreenivasmurthy SG, Zhu Z, Su CF, Liu J, Song JX, Lu JH, Tan JQ, Pan WD, Li M* & Cheung KH*(2021) “ Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease”. Autophagy. 29 June 2021. doi:10.1080/15548627.2021.1945220

Yang CB, Liu J, Tong BCK, Wang ZY, Zhu Z, Su CF, Sreenivasmurthy SG, Wu JX, Iyaswamy A, Krishnamoorthi SK, Huang SY, Cheung KH, Song JX, Tan JQ, Lu JH, Li M*(2021) “TFEB, a master regulator of autophagy and biogenesis, unexpected promotes apoptosis in response to the cyclopentenone prostaglandin 15d-PGJ2”. Acta Pharmacologica Sinica. 2 June 2021, doi:10.1038 /s41401- 021-00711-7

Wu MY, Cai CZ, Yang CB, Yue ZY, Chen Y, Bian ZX, Li M* & Lu JH* (2021) “Emerging roles of NRBF2/PI3KC3 axis in maintaining homeostasis of brain and guts”. Neural. Regen. Res. 13 April 2021. doi: 10.4103/1673-5374.317973

Su CF, Jiang L, Zhang XW, Iyaswamy A, Li M* (2021) “Resveratrol in Rodent Models of Parkinson’s Disease: A Systematic Review of Experimental Studies”. Frontiers in Pharma.  22 April 2021. doi: 10.3389/fphar.2021.644219

09203776, Natural small molecule Isorhamnetin and its optimized derivatives for Parkinson’s disease treatment by targeting TFEB-mediated autophagy. Prof. LI Min. HMRF. 01/12/22-30/11/25

Back